# OnCo record nct05155254 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05155254/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05155254", "NCT05155254" ;
  schema:name "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)"@en ;
  schema:description "A phase 3 trial testing IO102-IO103 in melanoma, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05155254/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05155254> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-05-17" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/io102-io103/> ;
  onco:companies <https://onco.cc/companies/io-biotech/> .